Petros Pharmaceuticals, Inc. (PTPI) stock
Close on Oct 19, 2026Market cap $135.07KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $135.07K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.19
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$3.20M
- EPS, diluted
- -$1.56
- Book value per share
- $0.01
- Diluted shares
- 47M
Trading
- Previous close
- $0.00
- Open
- $0.00
- Day's range
- $0.00 – $0.00
- Volume
- 159,160
- Average volume (20 days)
- 158,283
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | PTPI | S&P 500 | Difference | PTPI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -28.7% | +0.6% | −29.4 pts | ||
| 3 months | -37.2% | +3.4% | −40.6 pts | ||
| Year to date | -64.2% | +13.3% | −77.4 pts | ||
| 1 year | -87.8% | +16.6% | −104.4 pts | ||
| 3 years | -100.0% | +86.4% | −186.4 pts | -95.8% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.9 pts | -90.7% | +12.7% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Petros Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- Update
- Results
- Results
About Petros Pharmaceuticals
Pharmaceutical Preparations
Petros Pharmaceuticals, Inc. operates as a healthcare technology company focused on expanding consumer access to nonprescription pharmaceuticals. The company develops a proprietary integrated technology solutions platform designed to assist pharmaceutical companies in transitioning prescription drugs to over-the-counter status under regulatory frameworks for nonprescription drug products with an additional condition for nonprescription use. Its platform consists of a software-as-a-service solution for operationalizing commercialization, data exchange, and regulatory compliance, paired with software as a medical device to provide an assistive consumer self-selection interface. Petros targets pharmaceutical label owners, direct-to-consumer self-care companies, and emerging health technology firms seeking licensable commercialization pathways.
Company profile, executives and historyPetros Pharmaceuticals stock: common questions
What is Petros Pharmaceuticals's stock price?
PTPI closed at $0.00 on Oct 19, 2026, up 5.56% on the day.
What is Petros Pharmaceuticals's market cap?
Petros Pharmaceuticals was worth $135.07K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is PTPI's P/E ratio?
Petros Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$1.56), so it has no meaningful P/E ratio.
Does Petros Pharmaceuticals pay a dividend?
No. Petros Pharmaceuticals has not paid a cash dividend over the last twelve months.
How has PTPI stock performed over the past year?
Including dividends, PTPI returned -87.8% over the past year, against +16.6% for the S&P 500.
Who are Petros Pharmaceuticals's competitors?
Companies most similar to Petros Pharmaceuticals by business, industry and size include PTCHF, ENSC, RANI, ANL, PRPH.
See a number that looks wrong?